Shares of Atai Life Sciences NV ATAI tumbled about 44% in premarket trading on Friday after the company said a Phase 2a clinical trial evaluating a ketamine therapy for treatment-resistant depression did not meet the primary endpoint. Atai’s stock has declined 60.1% over the past year, while the S&P 500 SPX is down 19.0%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.